Replimune

$45.96
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.82 (+1.82%) As of 1:25 PM EST today

Why Robinhood?

You can buy or sell Replimune and other stocks, options, and ETFs commission-free!

About REPL

Replimune Group, Inc. Common Stock, also called Replimune, is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in and directly kill tumors, as well as induce a potent, patient-specific, anti-tumor immune response. The company was founded by Philip Astley-Sparke, Colin Love and Robert Coffin in March 2015 and is headquartered in Woburn, MA. The listed name for REPL is Replimune Group, Inc. Common Stock.

CEO
Philip Astley-Sparke
Employees
122
Headquarters
Woburn, Massachusetts
Founded
2015
Market Cap
2.10B
Price-Earnings Ratio
Dividend Yield
Average Volume
431.09K
High Today
$46.40
Low Today
$44.26
Open Price
$45.44
Volume
150.11K
52 Week High
$54.85
52 Week Low
$8.58

Collections

REPL Earnings

-$0.46
-$0.31
-$0.15
$0.00
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Estimated
per share
Actual
Expected Feb 11, Pre-Market

You May Also Like